Matches in SemOpenAlex for { <https://semopenalex.org/work/W155317839> ?p ?o ?g. }
Showing items 1 to 100 of
100
with 100 items per page.
- W155317839 endingPage "24" @default.
- W155317839 startingPage "3" @default.
- W155317839 abstract "Due to their wide spectrum of activity, good pharmacokinetics, established clinical efficacy and high tolerability, cephalosporins are among the most widely used antibiotics worldwide. The third and fourth generation cephalosporins are predominantly parenteral agents, administered two or three times daily, used in the treatment of a wide range of moderate to severe infections. Ceftriaxone, a third generation cephalosporin, is unique in exhibiting an unusually long elimination half-life that allows for once-daily administration. Among third generation cephalosporins, ceftazidime and cefoperazone are unusual among cephalosporins in possessing activity, albeit moderate, against Pseudomonas aeruginosa. However, both of these agents also exhibit marked loss of activity against Gram-negative organisms producing high levels of Class A or C beta-lactamases. Sulperazone, a 1:1 combination of cefoperazone and the beta-lactamase inhibitor sulbactam, is more resistant to attack by Class A beta-lactamases but remains vulnerable to isolates producing Class C beta-lactamases. Ceftriaxone exhibits the widest antibacterial spectrum of third generation cephalosporins and this is reflected in clinical responses. Cefoperazone and sulperazone exhibit the poorest clinical responses. Although the fourth generation cephalosporins cefpirome and cefepime exhibit enhanced stability to bacterial beta-lactamases and marginally enhanced in vitro antibacterial activity over ceftriaxone, there is no clinical advantage in terms of clinical or bacteriological success. The cephalosporins are well tolerated, with few and generally transient adverse effects; the major exception being haematological abnormalities including blood coagulation disorders associated with cefoperazone. Several pharmacoeconomic studies indicate that the once-daily dosing regimen required for ceftriaxone is the major factor responsible for its cost-effectiveness over third and fourth generation cephalosporins." @default.
- W155317839 created "2016-06-24" @default.
- W155317839 creator A5038953217 @default.
- W155317839 creator A5054182957 @default.
- W155317839 creator A5080892648 @default.
- W155317839 creator A5086233086 @default.
- W155317839 date "2005-02-01" @default.
- W155317839 modified "2023-10-01" @default.
- W155317839 title "In vitro activity, pharmacokinetics, clinical efficacy, safety and pharmacoeconomics of ceftriaxone compared with third and fourth generation cephalosporins: review." @default.
- W155317839 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15828439" @default.
- W155317839 hasPublicationYear "2005" @default.
- W155317839 type Work @default.
- W155317839 sameAs 155317839 @default.
- W155317839 citedByCount "13" @default.
- W155317839 countsByYear W1553178392012 @default.
- W155317839 countsByYear W1553178392015 @default.
- W155317839 countsByYear W1553178392016 @default.
- W155317839 countsByYear W1553178392017 @default.
- W155317839 countsByYear W1553178392019 @default.
- W155317839 countsByYear W1553178392020 @default.
- W155317839 countsByYear W1553178392021 @default.
- W155317839 countsByYear W1553178392023 @default.
- W155317839 crossrefType "journal-article" @default.
- W155317839 hasAuthorship W155317839A5038953217 @default.
- W155317839 hasAuthorship W155317839A5054182957 @default.
- W155317839 hasAuthorship W155317839A5080892648 @default.
- W155317839 hasAuthorship W155317839A5086233086 @default.
- W155317839 hasConcept C112705442 @default.
- W155317839 hasConcept C126322002 @default.
- W155317839 hasConcept C197934379 @default.
- W155317839 hasConcept C2776432923 @default.
- W155317839 hasConcept C2776520383 @default.
- W155317839 hasConcept C2776968632 @default.
- W155317839 hasConcept C2777050379 @default.
- W155317839 hasConcept C2777457247 @default.
- W155317839 hasConcept C2777637488 @default.
- W155317839 hasConcept C2778375690 @default.
- W155317839 hasConcept C2778478555 @default.
- W155317839 hasConcept C2779631663 @default.
- W155317839 hasConcept C501593827 @default.
- W155317839 hasConcept C523546767 @default.
- W155317839 hasConcept C54355233 @default.
- W155317839 hasConcept C64778159 @default.
- W155317839 hasConcept C71924100 @default.
- W155317839 hasConcept C86803240 @default.
- W155317839 hasConcept C89423630 @default.
- W155317839 hasConcept C94665300 @default.
- W155317839 hasConcept C98274493 @default.
- W155317839 hasConceptScore W155317839C112705442 @default.
- W155317839 hasConceptScore W155317839C126322002 @default.
- W155317839 hasConceptScore W155317839C197934379 @default.
- W155317839 hasConceptScore W155317839C2776432923 @default.
- W155317839 hasConceptScore W155317839C2776520383 @default.
- W155317839 hasConceptScore W155317839C2776968632 @default.
- W155317839 hasConceptScore W155317839C2777050379 @default.
- W155317839 hasConceptScore W155317839C2777457247 @default.
- W155317839 hasConceptScore W155317839C2777637488 @default.
- W155317839 hasConceptScore W155317839C2778375690 @default.
- W155317839 hasConceptScore W155317839C2778478555 @default.
- W155317839 hasConceptScore W155317839C2779631663 @default.
- W155317839 hasConceptScore W155317839C501593827 @default.
- W155317839 hasConceptScore W155317839C523546767 @default.
- W155317839 hasConceptScore W155317839C54355233 @default.
- W155317839 hasConceptScore W155317839C64778159 @default.
- W155317839 hasConceptScore W155317839C71924100 @default.
- W155317839 hasConceptScore W155317839C86803240 @default.
- W155317839 hasConceptScore W155317839C89423630 @default.
- W155317839 hasConceptScore W155317839C94665300 @default.
- W155317839 hasConceptScore W155317839C98274493 @default.
- W155317839 hasIssue "1" @default.
- W155317839 hasLocation W1553178391 @default.
- W155317839 hasOpenAccess W155317839 @default.
- W155317839 hasPrimaryLocation W1553178391 @default.
- W155317839 hasRelatedWork W1486848418 @default.
- W155317839 hasRelatedWork W2008330785 @default.
- W155317839 hasRelatedWork W2031491721 @default.
- W155317839 hasRelatedWork W2080995993 @default.
- W155317839 hasRelatedWork W2212288276 @default.
- W155317839 hasRelatedWork W224279172 @default.
- W155317839 hasRelatedWork W2280967608 @default.
- W155317839 hasRelatedWork W2319117663 @default.
- W155317839 hasRelatedWork W2398617228 @default.
- W155317839 hasRelatedWork W2467848500 @default.
- W155317839 hasRelatedWork W2563516446 @default.
- W155317839 hasRelatedWork W287746132 @default.
- W155317839 hasRelatedWork W2936767285 @default.
- W155317839 hasRelatedWork W3092954868 @default.
- W155317839 hasRelatedWork W3196449924 @default.
- W155317839 hasRelatedWork W3196802998 @default.
- W155317839 hasRelatedWork W3197360754 @default.
- W155317839 hasRelatedWork W3197859080 @default.
- W155317839 hasRelatedWork W3198487229 @default.
- W155317839 hasRelatedWork W2600607037 @default.
- W155317839 hasVolume "17" @default.
- W155317839 isParatext "false" @default.
- W155317839 isRetracted "false" @default.
- W155317839 magId "155317839" @default.
- W155317839 workType "article" @default.